HC Wainwright Reaffirms Buy Rating for Astria Therapeutics (NASDAQ:ATXS)

HC Wainwright restated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a $16.00 target price on the biotechnology company’s stock.

Several other brokerages have also recently commented on ATXS. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Oppenheimer boosted their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday. TD Cowen assumed coverage on Astria Therapeutics in a research note on Monday, July 29th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Astria Therapeutics presently has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $9.37 on Thursday. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90. The company has a market capitalization of $528.66 million, a PE ratio of -4.48 and a beta of 0.71. The company’s fifty day moving average is $11.40 and its 200-day moving average is $10.62.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors have recently modified their holdings of ATXS. FMR LLC increased its position in shares of Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after acquiring an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. grew its holdings in shares of Astria Therapeutics by 1.2% in the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after acquiring an additional 61,457 shares in the last quarter. Vestal Point Capital LP grew its stake in Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after buying an additional 480,184 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after buying an additional 218,518 shares in the last quarter. Institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.